AstraZeneca UK Marketing Company appoints new PresidentChris Brinsmead is to join AstraZeneca's UK Marketing Company as
Company President in January 2002. He will be responsible for overseeing the
1,800 employees and ensuring AZ maintains its leading position in the UK
market.
Chris Brinsmead is to join AstraZeneca's UK Marketing Company as
Company President in January 2002. He will be responsible for overseeing the
1,800 employees and ensuring AZ maintains its leading position in the UK
market.Chris has a track record of over twenty years in the industry.
He was formerly with ICI and Zeneca and most recently had global responsibility
in AstraZeneca for the Oncology portfolio of brands. Chris's expertise in
managing products in both the R&D and launch phases mean he is strongly
positioned to consolidate the company's position in the market place - bringing
the organisation's innovative and life changing products to patients in the UK.
Regional Vice President Europe, Ulf Sather commented: "The UK is
one of AstraZeneca's key markets. Chris's leadership and valuable experience
will be central to delivering commercial success from our strong pipeline and
ensuring growth through our exciting portfolio of products". The UKMC was formed two years ago following the merger of Astra
and Zeneca. It has been through a period of rapid growth and more recently
consolidation under Beverley Salt who has also overseen the extremely
successful launches of the PPI, Nexium, and the asthma treatment, Symbicort She
is taking on the role of Vice President, Strategic Planning with particular
emphasis on Asia, Latin America and Eastern Europe. Beverley will be based at
the global headquarters in London and report into Bruno Angelici, Executive
Vice President, International Sales & Marketing Organisation,
AstraZeneca.Ends
The core purpose of the UK Marketing Company is to create demand
for and sell AstraZeneca products. It is responsible for all customer interface
in the UK which includes an extensive clinical research programme, as well as
marketing, sales and customer services. The company has an impressive track
record being number one in terms of sales in Oncology, Gastroenterology and
Anaesthesia and number two in Respiratory and Cardiovascular markets in the UK.
This division of AZ UK now employs over 1,800 people who are split between the
headquarters in Luton, the field based clinical and commercial staff and the
Clinical Research Group in Scotland. The UKMC is the largest marketing division
within AstraZeneca outside the USA. AstraZeneca is based in the UK and is one of the world's leading
ethical pharmaceutical companies, with a powerful range of products designed to
fight disease in important areas of medical need. The company is research and
technology intensive with extensive marketing and development skills. It spends
over £5 million each working day on the global research and development
of innovative, effective medicines.
Further enquiries to:
Anna Isaacs Corporate Communications Manager AZ UK Marketing Company 01923 272 262 anna.isaacs@astrazeneca.com
